Cite
Dumbrava EI, Brusco L, Daniels M, et al. Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. JCO Precis Oncol. 2019;3doi: 10.1200/PO.18.00143.
Dumbrava, E. I., Brusco, L., Daniels, M., Wathoo, C., Shaw, K., Lu, K., Zheng, X., Strong, L., Litton, J., Arun, B., Eterovic, A. K., Routbort, M., Patel, K., Qi, Y., Piha-Paul, S., Subbiah, V., Hong, D., Rodon, J., Kopetz, S., Mendelsohn, J., Mills, G. B., Chen, K., & Meric-Bernstam, F. (2019). Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. JCO precision oncology, 3. https://doi.org/10.1200/PO.18.00143
Dumbrava, E Ileana, et al. "Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations." JCO precision oncology vol. 3 (2019). doi: https://doi.org/10.1200/PO.18.00143
Dumbrava EI, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00143. Epub 2019 Apr 11. PMID: 31517177; PMCID: PMC6741435.
Copy
Download .nbib